The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Pharmacogenetics (London)

• Publication date

  1997-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1097/00008571-199706000-00005PMID 9241660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

  1996cited by this paper
• Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).

  1996cited by this paper
• Histidine residues in rabbit liver microsomal cytochrome P-450 2B4 control electron transfer from NADPH-cytochrome P-450 reductase and cytochrome b5.

  1996cited by this paper
• Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

  1996cited by this paper
• Genetic analysis of the human cytochrome P450 CYP2C9 locus.

  1996cited by this paper
• The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

  1996cited by this paper
• Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

  1995cited by this paper
• The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.

  1995cited by this paper
• Role of Acidic Residues in the Interaction of NADPH-Cytochrome P450 Oxidoreductase with Cytochrome P450 and Cytochrome c(*)

  1995cited by this paper
• CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.

  1995cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes.

  1994cited by this paper
• Essential role of His163 of cytochrome P450 1A2 in catalytic functions associated with cytochrome b5.

  1994cited by this paper
• Specificity of the cytochrome P‐450 interaction with cytochromeb 5

  1994cited by this paper
• Influence of ionic strength on the P450 monooxygenase reaction and role of cytochrome b5 in the process.

  1994cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Probing the putative cytochrome P450- and cytochrome c-binding sites on NADPH-cytochrome P450 reductase by anti-peptide antibodies.

  1994cited by this paper
• Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450.

  1993cited by this paper
• Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver.

  1993cited by this paper
• Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.

  1993cited by this paper
• The role of cytochrome P450 lysine residues in the interaction between cytochrome P450IA1 and NADPH-cytochrome P450 reductase.

  1992cited by this paper
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

  1992cited by this paper
• Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.

  1992cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

  1964cited by this paper
• Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies.

  1962cited by this paper

• Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions

  2025cites this paper
• A Comparison of Molecular Techniques for Improving the Methodology in the Laboratory of Pharmacogenetics

  2024cites this paper
• Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.

  2024cites this paper
• A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes

  2024cites this paper
• Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer

  2024cites this paper
• Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants

  2023influential citation
• Variability in Human In Vitro Enzyme Kinetics.

  2021cites this paper
• Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells

  2021cites this paper
• Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study

  2021cites this paper
• Comparison of multivariate linear regression and a machine learning algorithm developed for prediction of precision warfarin dosing in a Korean population

  2021cites this paper
• Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells

  2021cites this paper
• Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects

  2021cites this paper
• Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism

  2020cites this paper
• Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy

  2020cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs

  2020cites this paper
• CYP2 C9 polymorphism among patients with oral squamous cell carcinoma and its role in altering the metabolism of benzo[a]pyrene.

  2020cites this paper
• Antikoagülan tedavisi alan hastalarda CYP2C9 gen polimorfizminin araştırılması

  2020cites this paper
• Dapsone activation of CYP2C9 allelic variants

  2020cites this paper
• Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats

  2020cites this paper
• Engineered human CYP2C9 and its main polymorphic variants for bioelectrochemical measurements of catalytic response.

  2020cites this paper
• Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism

  2020influential citation
• Pharmacogenomics in Clinical Care: Implications for Public Health

  2020cites this paper
• Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications

  2019cites this paper
• Personalized Medicine of Urate-Lowering Therapy for Gout

  2019cites this paper
• Functional Characterization of Pharmcogenetic Variants of Human Cytochrome P450 2C9 in Korean Populations

  2019cites this paper
• Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone

  2019cites this paper
• Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.

  2019cites this paper
• Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation.

  2019cites this paper
• PHARMACOGENETIQUE DE L’ACENOCOUMAROL : LES GENES IMPLIQUES DANS LA VARIABILITE DE LA REPONSE ET PROPOSITION D’UN ALGORITHME PREDICTIF DE LA DOSE POUR LA POPULATION MAROCAINE

  2019cites this paper
• Relevance of CYP2C9 Function in Valproate Therapy

  2018cites this paper
• The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.

  2018cites this paper
• Polymorphism of Cytochrome P450 epoxygenase and its association with Endothelial Dysfunction in Patients with Coronary Artery Disease

  2018cites this paper
• Different inhibitory effects of azole-containing drugs and pesticides on CYP2C9 polymorphic forms: An in vitro study.

  2018cites this paper
• Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations

  2018cites this paper
• Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population

  2018cites this paper
• University of Dundee Interaction between polymorphisms in aspirin metabolic pathways , regular aspirin use and colorectal cancer

  2018cites this paper
• Effets du diabète de type 2 sur l’expression et l’activité des cytochromes P450 hépatiques et extra-hépatiques chez la souris C57BL/6 sous une diète riche en gras

  2017cites this paper
• Risk of development of hemorrhagic complications due to warfarin therapy

  2017cites this paper
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†

  2017cites this paper
• Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study

  2017cites this paper
• Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.

  2017cites this paper
• Clinical Weighting of Drug–Drug Interactions in Hospitalized Elderly

  2016cites this paper
• Genetic determinants of response and adverse effects following vitamin K antagonist oral anticoagulants

  2016cites this paper
• The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism.

  2016cites this paper
• Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes

  2016cites this paper
• Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells

  2016cites this paper
• Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization.

  2016cites this paper
• Pharmacogenetics of drug-metabolizing enzymes in US Hispanics

  2015cites this paper
• Mechanistic basis of electron transfer to cytochromes p450 by natural redox partners and artificial donor constructs.

  2015cites this paper
• Pharmacogenetics of healthy volunteers in Puerto Rico

  2015cites this paper
• microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.

  2015cites this paper
• Pharmacogenetic considerations in the treatment of gout.

  2015cites this paper
• Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR

  2015cites this paper
• Erblichkeit in der Aktivität der Enzyme CYP2D6 und CYP2C9 sowie des Transporters OATP1B1 unter Berücksichtigung der bereits bekannten genetischen Varianten

  2014cites this paper
• Variability in human in vitro enzyme kinetics.

  2014cites this paper
• MutaCYP: Classification of missense mutations in human cytochromes P450

  2014influential citation
• Pharmacogenetic biomarkers for predicting drug response

  2014cites this paper
• p-Aminothiophenol modification on gold surface improves stability for electrochemically driven cytochrome P450 microsome activity

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.

  2014cites this paper
• Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat

  2014cites this paper
• CYP2C0, VKORC1 and CYP4F2 Variant Frequencies in Patients on either Low or High Stable Warfarin Maintenance Therapy in the Ghanaian Population

  2014cites this paper
• Pharmacogenomics of Warfarin

  2014cites this paper
• Cytochrome P450 pharmacogenetics : implications for anticancer and warfarin therapy

  2014cites this paper
• Correction: Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin

  2013cites this paper
• Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.

  2013cites this paper
• Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain

  2013cites this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cites this paper
• In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability

  2013cites this paper
• Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps.

  2013cites this paper
• High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase

  2013cites this paper
• Towards optimal dosing of coumarin derivatives: the role of pharmacogenetics

  2013cites this paper
• Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms

  2013cites this paper
• Genetic and Environmental Factors

  2013cites this paper
• Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region

  2013cites this paper
• Pharmacogenetics of analgesic drugs

  2013cites this paper
• Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine

  2013cites this paper
• An acenocoumarol dose algorithm based on a South-Eastern European population

  2013cites this paper
• Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin

  2013cites this paper
• interindividual variability in the dose-anticoagulant effect of warfarin A polymorphism in the VKORC1 gene is associated with an

  2013cites this paper
• Identification of the factors influencing anticoagulation response to warfarin in children

  2012cites this paper
• Chapter 7: Pharmacogenomics

  2012cites this paper
• Anticoagulation par antivitamines K: analyse des interactions médicamenteuses et des polymorphismes génétiques à l'origine de la variabilité de la réponse et des risques liés à l'acénocoumarol

  2012cites this paper
• Pharmacogenomics Aspect of Warfarin Therapy

  2012cites this paper
• Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

  2012cites this paper
• Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

  2012cites this paper
• Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity

  2012cites this paper
• Study of polymorphism frequency of 1639G> A gene from VKORC1 in patients with cardiovascular disorders in the northwestern area of Iran

  2012cites this paper
• Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose.

  2012cites this paper
• Cytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques

  2012cites this paper
• A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)

  2012cites this paper
• patient with atypical long (55 years) malignant melanoma process Wstępne badania genetyczne pacjenta o nietypowo długim (55 lat) przebiegu czerniaka złośliwego

  2012cites this paper
• Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes

  2012cites this paper
• Genetic determinants for metabolic abnormalities

  2012cites this paper
• Meta-Analysis of Cytochrome P-450 2C9 Polymorphism and Colorectal Cancer Risk

  2012cites this paper
• Preliminary genetic investigation of the patient with atypical long (55 years) malignant melanoma process

  2012cites this paper
• Pharmacogenetics of nonsteroidal anti-inflammatory drugs

  2012cites this paper
• Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals

  2012cites this paper
• ASSOCIATION OF GENETIC AND NONGENETIC VARIABILITIES WITH PHENYTOIN AND CARBAMAZEPINE RESPONSE PHENOTYPES

  2012cites this paper
• Pharmacology of Vitamin K Antagonists

  2011cites this paper